Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Embry Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Embry Holdings şirketinin toplam hissedar öz sermayesi HK$2.0B ve toplam borcu HK$267.5M olup, bu da borç-öz sermaye oranını 13.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla HK$2.7B ve HK$651.8M dir.

Anahtar bilgiler

13.2%

Borç/özkaynak oranı

HK$267.50m

Borç

Faiz karşılama oranı	n/a
Nakit	HK$227.84m
Eşitlik	HK$2.03b
Toplam yükümlülükler	HK$651.85m
Toplam varlıklar	HK$2.68b

Son finansal sağlık güncellemeleri

Does Embry Holdings (HKG:1388) Have A Healthy Balance Sheet?

Sep 30

Recent updates

Benign Growth For Embry Holdings Limited (HKG:1388) Underpins Its Share Price

Oct 02

Improved Revenues Required Before Embry Holdings Limited (HKG:1388) Shares Find Their Feet

Feb 06

Does Embry Holdings (HKG:1388) Have A Healthy Balance Sheet?

Sep 30

Capital Allocation Trends At Embry Holdings (HKG:1388) Aren't Ideal

Jul 20

Looking For Steady Income For Your Dividend Portfolio? Is Embry Holdings Limited (HKG:1388) A Good Fit?

Mar 21

Our Take On The Returns On Capital At Embry Holdings (HKG:1388)

Feb 21

Would Shareholders Who Purchased Embry Holdings' (HKG:1388) Stock Five Years Be Happy With The Share price Today?

Dec 19

Our Take On The Returns On Capital At Embry Holdings (HKG:1388)

Nov 23

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 1388 'nin kısa vadeli varlıkları ( HK$811.1M ) kısa vadeli yükümlülüklerini ( HK$364.9M ) aşıyor.

Uzun Vadeli Yükümlülükler: 1388 şirketinin kısa vadeli varlıkları ( HK$811.1M ) uzun vadeli yükümlülüklerini ( HK$286.9M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 1388 'nin net borç/öz sermaye oranı ( 2% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: 1388 'nin borç/öz sermaye oranı son 5 yılda 22.4% seviyesinden 13.2% seviyesine düştü.

Borç Kapsamı: 1388 'nin işletme nakit akışı negatif olduğundan borçlar iyi karşılanamıyor.

Faiz Kapsamı: 1388 şirketinin borçlarına ilişkin faiz ödemelerinin EBIT tarafından iyi bir şekilde karşılanıp karşılanmadığını belirlemek için yeterli veri yok.

Embry Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Does Embry Holdings (HKG:1388) Have A Healthy Balance Sheet?

Recent updates

Benign Growth For Embry Holdings Limited (HKG:1388) Underpins Its Share Price

First half 2024 earnings released: HK$0.20 loss per share (vs HK$0.013 profit in 1H 2023)

Embry Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

Full year 2023 earnings released: HK$0.17 loss per share (vs HK$0.12 loss in FY 2022)

Embry Holdings Limited, Annual General Meeting, May 23, 2024

Full year 2023 earnings released: HK$0.17 loss per share (vs HK$0.12 loss in FY 2022)

Embry Holdings Limited to Report Fiscal Year 2023 Results on Mar 21, 2024

Improved Revenues Required Before Embry Holdings Limited (HKG:1388) Shares Find Their Feet

Embry Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 December 2023

First half 2023 earnings released: EPS: HK$0.013 (vs HK$0.003 in 1H 2022)

Embry Holdings Limited to Report First Half, 2023 Results on Aug 24, 2023

Embry Holdings Appoints Mr. Chan Chi on as Director

Full year 2022 earnings released: HK$0.12 loss per share (vs HK$0.065 loss in FY 2021)

Embry Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 December 2022

Less than half of directors are independent

Embry Holdings Limited Provides Sales Guidance for the Full Year Ending 31 December 2022

Does Embry Holdings (HKG:1388) Have A Healthy Balance Sheet?

First half 2022 earnings released: EPS: HK$0.003 (vs HK$0.078 in 1H 2021)

Embry Holdings Limited Provides Profit Guidance for Six Months Ended 30 June 2021

Less than half of directors are independent

Embry Holdings Limited Provides Earnings Guidance for the Year Ended December of 2021

Embry Holdings Limited Announces Resignation of Mr. Cheng Man Tai as Executive Director and Chairman, Effective 1 February 2022

Upcoming dividend of HK$0.02 per share

First half 2021 earnings released: EPS HK$0.078 (vs HK$0.092 loss in 1H 2020)

Embry Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021

Capital Allocation Trends At Embry Holdings (HKG:1388) Aren't Ideal

Embry Holdings Limited Approves Final Dividend for the Year Ended 31 December 2020

Upcoming dividend of HK$0.025 per share

Embry Holdings Limited Provides Group Financial Guidance for the First Quarter Ended 31 March 2021

Full year 2020 earnings released: HK$0.007 loss per share (vs HK$0.19 profit in FY 2019)

Looking For Steady Income For Your Dividend Portfolio? Is Embry Holdings Limited (HKG:1388) A Good Fit?

Embry Holdings Limited Proposes Final Dividend, Payable on 10 June 2021

Full year 2020 earnings released: HK$0.007 loss per share (vs HK$0.19 profit in FY 2019)

Embry Holdings Limited to Report Fiscal Year 2020 Final Results on Mar 18, 2021

New 90-day high: HK$1.11

Our Take On The Returns On Capital At Embry Holdings (HKG:1388)

New 90-day high: HK$1.05

Would Shareholders Who Purchased Embry Holdings' (HKG:1388) Stock Five Years Be Happy With The Share price Today?

Our Take On The Returns On Capital At Embry Holdings (HKG:1388)

New 90-day low: HK$0.99

New 90-day low: HK$1.00

First half earnings released

Earnings released

Embry Holdings Limited to Report First Half, 2020 Results on Aug 20, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin